ZAVESCA (miglustat) capsules
Zavesca is a glucosylceramide synthase inhibitor indicated as monotherapy for treatment of adult patients with mild/moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option.
Home | miglustat capsules
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient inquires under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
ZAVESCA (miglustat) capsules
Miglustat, sold under the brand name Zavesca among others, is a medication used to treat type I Gaucher disease (GD1) and Pompe disease. It is also known as N-butyldeoxynojirimycin, and is a derivative of the anti-diabetic 1-deoxynojirimycin.
Zavesca is a prescription medicine used alone to treat adults with mild to moderate type 1 Gaucher disease. Zavesca is used only in people who cannot be treated with
enzyme replacement therapy. It is not known if Zavesca is safe and effective in children under 18 years of age. Active ingredient: miglustat. Inactive ingredients: sodium starch glycollate, povidone (K30), and magnesium stearate.
Miglustat is indicated to treat adults with mild to moderate type I Gaucher disease for whom enzyme replacement therapy is unsuitable. In the EU, miglustat (Opfolda), in combination with cipaglucosidase alfa, is a long-term enzyme replacement therapy in adults with late-onset Pompe disease (acid α‑glucosidase [GAA] deficiency).
Drug (Brand / Generic): ZAVESCA / miglustat
Current Indications: chronic mild to moderate type 1 Gaucher disease
Marketed by:: Actelion
Approval Date: 2003
Available as (Form & Strength): Capsules: 100 mg. The capsule shell contains: gelatin and titanium dioxide; the edible printing ink contains black iron oxide and shellac.
Find Reference Updates
Alleviare Life Sciences
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “ZAVESCA (miglustat) capsules”. Confirmation of the order for ZAVESCA (miglustat) capsules will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
Get Access to Treatment – ZAVESCA
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha